Stockscreener 앱 받기
232.63
0.72%
1.66
시간 외 거래:
232.63
Quest Diagnostics Inc 주식(DGX)의 최신 뉴스
Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investors - ChartMill
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 - www.marketscreener.com
Quest Diagnostics Incorporated (DGX) options chain - Yahoo Finance UK
Quest Diagnostics (DGX) Announces Executive Leadership Transitio - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 - TradingView
Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating - www.marketscreener.com
Quest Diagnostics Inc's Dividend Analysis - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Rides Steady Testing Demand - Kalkine Media
Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
DGX5874579 Bond Profile: Coupon and Redemption - TradingView
Three Days Left To Buy Quest Diagnostics Incorporated (NYSE:DGX) Before The Ex-Dividend Date - Moomoo
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8 - ChartMill
Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - TradingView
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - Yahoo Finance
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance
Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - Pluang
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha
Quest Diagnostics Inc (DGX) Stock Down 4.1% but Still Overvalued -- GF Score: 74/100 - GuruFocus
Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 - Yahoo Finance
Why Quest Diagnostics Holdings Stock Dropped Today - Yahoo Finance
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - Your Wyoming Link
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - finance.yahoo.com
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - marketscreener.com
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - Yahoo Finance
Is This the Right Time to Add DGX Stock to Your Portfolio? - TradingView
Is This the Right Time to Add DGX Stock to Your Portfolio? - Zacks Investment Research
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Is Quest Diagnostics Stock Outperforming the Nasdaq? - Barchart.com
Is Quest Diagnostics Stock Outperforming the Nasdaq? - Yahoo Finance
Evercore sees Lab Corp, Quest shares facing Medicare pricing headwind By Investing.com - Investing.com Canada
Labcorp, Quest fall as CMS cuts 2027 rates for laboratory services (LH:NYSE) - Seeking Alpha
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - Yahoo Finance
Beat the Market Like Zacks: PBF, Palantir, Adobe in Focus - Zacks Investment Research
Nearly 1 in 3 people with Lyme antibodies had others too. A parasite found alongside Lyme needs different treatment. - Stock Titan
Truist Raises Price Target on Quest Diagnostics to $260 From $250, Keeps Hold Rating - marketscreener.com
Quest Diagnostics (DGX) Q1 2026 Earnings Call Transcript - fortune.com
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
96% say lab tests matter as Medicare cuts approach - Stock Titan
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
1.08%
2.79%
자본화:
|
볼륨(24시간):